An American on a fixed income pays 2.78 times more for their prescription drugs than someone in Germany, France, or Japan paying for the identical molecule. For brand-name drugs, the ratio reaches 4.22 times what patients in other wealthy nations pay, according to RAND Corporation research covering 33 OECD countries. The United States represents just 24% of global prescription volume but accounts for 62% of global pharmaceutical revenue. The math only runs in one direction for the companies setting those prices.
How the Gap Was Built
For 20 years after Medicare Part D was created in 2003, federal law explicitly prohibited Medicare from negotiating drug prices with manufacturers. The program was designed to buy at list prices. That prohibition cost Medicare an estimated tens of billions annually in excess payments. Pharmaceutical companies could set prices knowing that the single largest purchaser in the country had no legal authority to push back.
Insulin is the sharpest example of what that system produced. By 2022, U.S. insulin prices were nearly 10 times higher than prices in 33 OECD comparison countries, and more than 10 times the prices in France and the United Kingdom. A product invented in 1921, whose original patent expired more than a century ago, cost Americans more per vial than a week of groceries in most states.
The Inflation Reduction Act of 2022 ended the negotiation ban for a limited set of high-cost drugs with no generic competition. In the first round of negotiations, ten drugs were selected and prices dropped by 38% to 85% from list. In the second round, Ozempic, Wegovy, and Rybelsus (diabetes and obesity drugs with list prices around $1,000 per month) were negotiated to a 71% discount for Medicare beneficiaries starting in 2026.
The Rollback Already Underway
The CBO estimated the IRA's negotiation program would save Medicare $98.5 billion over its full implementation period. Before that program reached full scale, the One Big Beautiful Bill Act (signed July 4, 2025) broadened exemptions for orphan drugs designated for multiple rare diseases, which the CBO calculated will cost Medicare $8.8 billion in additional spending. The specific drugs shielded from negotiation include blockbuster cancer treatments: Keytruda, Opdivo, and Darzalex. That is nearly 10% of projected savings handed back to pharmaceutical companies via a legislative carve-out.
The rollback did not stop there. The Center for American Progress documented that additional administrative modifications to the IRA negotiation rules further diminished projected savings beyond what the statute alone accomplished. Meanwhile, RAND's 2024 analysis confirmed the underlying structural gap: U.S. drug prices average 2.78 times other nations' rates overall, with brand drugs at 4.22 times. Generic drugs, which represent 90% of U.S. prescription volume, are actually cheaper in the U.S. than abroad. The entire price disparity is in branded pharmaceuticals, where manufacturers face no competition and buyers, until recently, had no legal leverage.
The United States represents 24% of global prescription volume but pays 62% of global pharmaceutical revenue. That ratio is the margin pharmaceutical companies have lobbied, litigated, and legislated to protect for two decades.
Every high-income country that pays less for drugs than the U.S. does so through the same basic mechanism: a central buyer or regulator with legal authority to say no. Some use reference pricing tied to what other countries pay. Some negotiate directly. All of them start from the position that a government purchasing drugs for millions of citizens holds leverage and should use it. The IRA established that principle for Medicare in limited form in 2022. The question now is whether that principle survives the next round of legislative revisions, or whether 62% of global pharmaceutical revenue continues flowing from one country that spent 20 years legally prohibited from bargaining.
Sources
- RAND: Prescription Drug Prices in the U.S. Are 2.78 Times Those in Other Countries
- KFF Health System Tracker: How Medicare Negotiated Drug Prices Compare to Other Countries
- Center for American Progress: Medicare Negotiation Is Working, but Rollbacks Diminish Potential Savings
- Senate Finance Committee: CBO Report on Big Ugly Bill's $8.8 Billion Pharmaceutical Handout
- NPR: Medicare Negotiated 71% Off Ozempic and Wegovy
- Commonwealth Fund: How Prices for the First 10 Medicare Negotiated Drugs Compare Internationally
Independent. Unfiltered. Unbought.
This is independent, sourced accountability reporting by Impeach 47. No corporate owners, no paywall.
Get new posts delivered free by email: impeachh47.substack.com.
Follow on X: @Impeach_47.
Follow on Threads: @impeach.47.
Follow on Instagram: @impeach.47.
Subscribe on YouTube: @impeach_47.
If this reporting is useful, the way you support us is simple: wear the movement. Every hat, shirt, and sticker from impeach47.earth is a walking billboard and the thing that keeps this research fed.
